| Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia SG O'Brien, F Guilhot, RA Larson, I Gathmann, M Baccarani, F Cervantes, ... New England Journal of Medicine 348 (11), 994-1004, 2003 | 4633 | 2003 |
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia BJ Druker, F Guilhot, SG O'Brien, I Gathmann, H Kantarjian, N Gattermann, ... New England Journal of Medicine 355 (23), 2408-2417, 2006 | 4388 | 2006 |
| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ... Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013 | 2555 | 2013 |
| Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop … FX Mahon, D Réa, J Guilhot, F Guilhot, F Huguet, F Nicolini, L Legros, ... The lancet oncology 11 (11), 1029-1035, 2010 | 1735 | 2010 |
| European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia A Hochhaus, M Baccarani, RT Silver, C Schiffer, JF Apperley, F Cervantes, ... Leukemia 34 (4), 966-984, 2020 | 1216 | 2020 |
| Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study S Castaigne, C Pautas, C Terré, E Raffoux, D Bordessoule, JN Bastie, ... The Lancet 379 (9825), 1508-1516, 2012 | 1075 | 2012 |
| Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials N Boissel, MF Auclerc, V Lhéritier, Y Perel, X Thomas, T Leblanc, ... Journal of Clinical Oncology 21 (5), 774-780, 2003 | 743 | 2003 |
| Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years P Rousselot, F Huguet, D Rea, L Legros, JM Cayuela, O Maarek, ... Blood 109 (1), 58-60, 2007 | 704 | 2007 |
| Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis J Cortes, P Rousselot, DW Kim, E Ritchie, N Hamerschlak, S Coutre, ... Blood 109 (8), 3207-3213, 2007 | 571 | 2007 |
| Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial S Saussele, J Richter, J Guilhot, FX Gruber, H Hjorth-Hansen, A Almeida, ... The Lancet Oncology 19 (6), 747-757, 2018 | 543 | 2018 |
| Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial H Kantarjian, R Pasquini, N Hamerschlak, P Rousselot, J Holowiecki, ... Blood, The Journal of the American Society of Hematology 109 (12), 5143-5150, 2007 | 539 | 2007 |
| Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia G Etienne, J Guilhot, D Rea, F Rigal-Huguet, F Nicolini, A Charbonnier, ... Journal of Clinical Oncology 35 (3), 298-305, 2017 | 494 | 2017 |
| Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped … P Rousselot, A Charbonnier, P Cony-Makhoul, P Agape, FE Nicolini, ... J Clin Oncol 32 (5), 424-430, 2014 | 481 | 2014 |
| Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia C Preudhomme, J Guilhot, FE Nicolini, A Guerci-Bresler, F Rigal-Huguet, ... New England Journal of Medicine 363 (26), 2511-2521, 2010 | 475 | 2010 |
| Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation R Nasr, MC Guillemin, O Ferhi, H Soilihi, L Peres, C Berthier, P Rousselot, ... Nature medicine 14 (12), 1333-1342, 2008 | 435 | 2008 |
| Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH … A de Labarthe, P Rousselot, F Huguet-Rigal, E Delabesse, F Witz, ... Blood 109 (4), 1408-1413, 2007 | 427 | 2007 |
| Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia Y Chalandon, X Thomas, S Hayette, JM Cayuela, C Abbal, F Huguet, ... Blood, The Journal of the American Society of Hematology 125 (24), 3711-3719, 2015 | 392 | 2015 |
| BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia MS Zabriskie, CA Eide, SK Tantravahi, NA Vellore, J Estrada, FE Nicolini, ... Cancer cell 26 (3), 428-442, 2014 | 344 | 2014 |
| Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study D Rea, FE Nicolini, M Tulliez, F Guilhot, J Guilhot, A Guerci-Bresler, ... Blood, The Journal of the American Society of Hematology 129 (7), 846-854, 2017 | 335 | 2017 |
| Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic … NP Shah, DW Kim, H Kantarjian, P Rousselot, PED Llacer, A Enrico, ... haematologica 95 (2), 232, 2010 | 335 | 2010 |
